Serum Proteomics in Dementia : Discovery and Validation of Biomarkers
Year: 2013
Type: article
Abstract: Dementia is a syndrome due to disease of the brain, usually of a chronic or progressive nature, \nin which there is disturbance of multiple higher cortical functions, including memory, thinking, \norientation, comprehension, calculation, learning capacity, language, and judgement. \nConsciousness is not clouded. The impairments of cognitive function are commonly \naccompanied, and occasionally preceded, by deterioration in emotional control, social \nbehaviour, or motivation. This syndrome occurs in Alzheimer’s disease, in cerebrovascular \ndisease, and in other conditions primarily or secondarily affecting the brain (World Health \nOrganization’s International Classification of Diseases (ICD-10, version 2007)). It is estimated \nthat there are currently 35.6 million people with dementia around the world and that this \nnumber will nearly double every 20 years, to 65.7 million in 2030 and 115.4 million in \n2050. Dementia mainly affects the elderly; after 65 years of age the prevalence doubles \nwith every five-year increase in age. The most common types of dementia are Alzheimer’s \ndisease (AD; 50-70%), vascular dementia (VaD; 20-30%), frontotemporal dementia (5- \n10%) and dementia with Lewy bodies (<5%)1. The borders between the different types \nare not at all strict, most of the times a mix of various types is observed. This is particularly \ntrue for AD and VaD, and AD and dementia with Lewy bodies. In a large autopsy study of \n1050 elderly demented individuals, 86% had AD related pathology. From this percentage \nonly 43% had pure AD, 23% had mixed AD and VaD and 11% had AD with Lewy bodies.
Author: Linda IJsselstijn
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2113044781